Skip to main content
Log in

Treatment of chronic hepatitis C with high-dose interferon α-2b

A multicenter study

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

A comparative study of three different high-dose regimens of interferon-α-2b (IFN) was conducted in patients with chronic hepatitis C to determine which was better at obtaining a sustained remission. A total of 126 patients were assigned randomly to one of three groups: group A was given 10 million international units (MIU) of IFN six times a week for eight weeks; group B was given 10 MIU IFN six times a week for four weeks followed by three times a week for an additional eight weeks; group C was given 10 MIU IFN six times a week for two weeks followed by three times a week for 12 weeks. The total dose administered to each group was 480 MIU/patient. Only the dosing schedule varied among the three groups. Among 98 efficacy-evaluable patients, a sustained alanine aminotransferase (ALT) response, defined as persistent normalization of the ALT for greater than six months after the termination of treatment, was achieved in 21.2% (7/33) of group A, 42.3% (11/26) of group B, and 54.5% (18/33) of group C patients. Similarly, a sustained loss of measurable serum hepatitis C virus RNA was observed in 28.6% (8/28) of group A, 40.9% (9/22) of group B, and 48.3% (14/29) of group C patients. Based upon these data, it can be concluded that 10 MIU of IFN administered six days a week for two weeks followed by three times a week for an additional 12 weeks produces the highest rate of both biochemical and virological responses to IFN therapy in patients with chronic HCV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hoofnagle JH, Mullen KD, Jones DB, et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315:1575–1578, 1986

    Google Scholar 

  2. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506, 1989

    Google Scholar 

  3. DiBisceglie AM, Martin P, Kassianides C, et al: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510, 1989

    Google Scholar 

  4. Kuo G, Choo QL, Alter HJ, et al: An assay for circulating antibodies to a major etiologic virus of human non-a, non-B chronic hepatitis. Science 244:362–364, 1989

    Google Scholar 

  5. Van der Poel CL, Cuypers HTM, Rees'nk HW, et al.: Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 337:317–319, 1991

    Google Scholar 

  6. Yousefi S, Escober MR, Gouldin CW: A practical cytopathic effect on dye uptake interferon assay for routine use in the clinical laboratory. Am J Clin Pathol 83:736–740, 1984

    Google Scholar 

  7. Shindo M, Okuno T, Matsumoto M, et al: Serum 2′, 5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology 8:366–370, 1988

    Google Scholar 

  8. Okamoto H, Okada S, Sugiyama Y, et al.: Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 60:215–222, 1990

    Google Scholar 

  9. Fujioka S, Hino K, Yasuda S, et al.: Interferon treatment in chronic non-A, non-B, hepatitis.In Viral Hepatitis C, D, and E. T Shikata, RH Purcell, T Uchida, et al (eds.). Amsterdam, Elsevier Science Publishers BV, 1991, pp 167–170

    Google Scholar 

  10. Hino S, Suzuki H, Yamamoto S, et al: A comparative study of interferon α-2b for the treatment of chronic hepatitis C. Clin Rep 16:409–442, 1992 (in Japanese)

    Google Scholar 

  11. Kakumu S, Arao M, Yoshioka K, et al.: Pilot study of recombinant human α-interferon for chronic non-A, non-B hepatitis. Am J Gastroenterol 84(1):40–45, 1989

    Google Scholar 

  12. Kakumu S, Arao M, Yoshioka K, et al: Recombinant human α-interferon therapy for chronic non-A, non-B hepatitis: Second report. Am J Gastroenterol 85(6):655–659, 1990

    Google Scholar 

  13. Iino S, Hino K, Kondo T, et al.: Interferon therapy for non-A, non-B chronic hepatitis. Gastroenterol Jpn 26(suppl 3):224–229, 1991

    Google Scholar 

  14. Merigan T, Sikora K, Breeden JH: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299:1449, 1978

    Google Scholar 

  15. Hino K, Kondo T, Kaku K, et al.: Biologic effects of IFN in patients with chronic hepatitis B.In Viral Hepatitis and Hepatocellular Carcinoma. J-L Sung, D-S Chen (eds). Hong Kong, Excerpta Medica, 1990; pp 345–354

    Google Scholar 

  16. Freund M, Von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoka H: Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependence of response and frequency of neutralizing anti-interferon antibodies. Brit J Haematol 72:350–356, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iino, S., Hino, K., Kuroki, T. et al. Treatment of chronic hepatitis C with high-dose interferon α-2b. Digest Dis Sci 38, 612–618 (1993). https://doi.org/10.1007/BF01316789

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01316789

Key Words

Navigation